GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Other Current Receivables

BCAX (Bicara Therapeutics) Other Current Receivables : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Other Current Receivables?

Bicara Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2025 was $0.00 Mil.


Bicara Therapeutics Other Current Receivables Historical Data

The historical data trend for Bicara Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Other Current Receivables Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Other Current Receivables
- - -

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Current Receivables Get a 7-Day Free Trial - - - - -

Bicara Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Bicara Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicara Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.